Good Clean Clinical Care Launches Microbiome-First Telehealth Platform for Women's Health

New Clinical Model Pairs Microbiome Testing and Specialist Care with BiomeNourish™, a Proprietary Prescription Base Built on Bio-Match® Technology, Designed for Vaginal Health

PORTLAND, Ore., Sept. 10, 2026 /PRNewswire/ -- Good Clean Clinical Care (GCCC) announces the launch of its microbiome-first telehealth platform, introducing a new model of vaginal healthcare that combines advanced testing, specialist clinical care, and personalized compounded treatments. Created for women experiencing chronic and unresolved vaginal health symptoms, GCCC is designed to move care beyond trial-and-error treatment toward greater precision informed by each patient's vaginal microbiome.

Vaginal health conditions affect millions of women and account for an estimated $20 billion in annual healthcare costs. More than half of women experience a recurrence within six months of treatment for vaginal infections, often leading to repeated courses of antibiotics, antifungals or other treatments. These approaches may provide short-term relief without addressing underlying imbalances in the vaginal microbiome that can contribute to recurrence. GCCC was developed to address this gap by evaluating the vaginal microbial environment before determining a course of care.

"Women have spent far too long being told that recurring vaginal symptoms are something they just have to live with," said Wendy Strgar, founder of Good Clean Clinical Care and Good Clean Love. "For more than 20 years, I've been working to change the way we understand and care for the vaginal microbiome. Good Clean Clinical Care is the culmination of that work and a step toward a future where women can expect more from their healthcare—more answers, more personalization, and care that takes their experiences seriously."

At the center of the GCCC model is an advanced 56-target qPCR vaginal microbiome test, designed to provide a more comprehensive picture of the vaginal microbial environment. Patients complete testing and meet virtually with GCCC-approved clinicians experienced in complex vaginal health, who evaluate the results alongside symptoms and medical history to develop an individualized care plan.

When treatment is appropriate and necessary, GCCC can provide custom-compounded prescriptions using BiomeNourish™, a first-of-its-kind prescription base formulated specifically for the vaginal and vulvar microbiome and developed from more than two decades of Bio-Match® formulation science. Rooted in the principles of biomimicry, BiomeNourish™ is designed to work with, rather than disrupt, the vaginal environment by matching the pH and osmolality associated with a healthy vaginal microbiome.

The science behind GCCC is also informed by the VENUS Study, led by Vaginal Biome Science (VBS), a biotechnology company advancing microbiome-driven solutions for vaginal health. One of the largest vaginal microbiome research initiatives of its kind, VENUS examines the vaginal microbiome across 12 gynecological conditions at the time of diagnosis to deepen understanding of microbial patterns and their relationship to vaginal health.

"Good Clean Clinical Care puts our growing understanding of the vaginal microbiome into practice, creating a stronger foundation for more personalized care," said Kim Capone, PhD, Chief Scientific Officer at GCCC and lead researcher of the VENUS Study.

Good Clean Clinical Care is now available at https://goodcleanclinicalcare.com/.

About Good Clean Clinical Care
Good Clean Clinical Care™ is the next evolution in vaginal health: where prescription compounding meets microbiome science. GCCC combines advanced microbiome testing, specialist clinical care and personalized compounded treatments using BiomeNourish™, a proprietary prescription base built on patented Bio-Match® Technology.

SOURCE Good Clean Clinical Care